Your browser doesn't support javascript.
loading
The impact of prognostic group classification on prostate cancer progression in intermediate-risk patients according to the European Association of Urology system: results in 479 patients treated with robot-assisted radical prostatectomy at a single tertiary referral center.
Porcaro, Antonio Benito; Bianchi, Alberto; Panunzio, Andrea; Gallina, Sebastian; Tafuri, Alessandro; Serafin, Emanuele; Orlando, Rossella; Mazzucato, Giovanni; Vidiri, Stefano; D'Aietti, Damiano; Montanaro, Francesca; Marafioti Patuzzo, Giulia; Artoni, Francesco; Baielli, Alberto; Ditonno, Francesco; Rizzetto, Riccardo; Veccia, Alessandro; Gozzo, Alessandra; De Marco, Vincenzo; Brunelli, Matteo; Cerruto, Maria Angela; Antonelli, Alessandro.
Affiliation
  • Porcaro AB; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, Verona 37126, Italy.
  • Bianchi A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Panunzio A; Department of Urology, Vito Fazzi Hospital, Lecce, Italy.
  • Gallina S; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Tafuri A; Department of Urology, Vito Fazzi Hospital, Lecce, Italy.
  • Serafin E; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Orlando R; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Mazzucato G; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Vidiri S; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • D'Aietti D; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Montanaro F; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Marafioti Patuzzo G; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Artoni F; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Baielli A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Ditonno F; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Rizzetto R; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Veccia A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Gozzo A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • De Marco V; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Brunelli M; Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Cerruto MA; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Antonelli A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Ther Adv Urol ; 16: 17562872241229260, 2024.
Article in En | MEDLINE | ID: mdl-38348129
ABSTRACT

Background:

Treatment outcomes in intermediate-risk prostate cancer (PCa) may be impaired by adverse pathology misclassification including tumor upgrading and upstaging. Clinical predictors of disease progression need to be improved in this category of patients.

Objectives:

To identify PCa prognostic factors to define prognostic groups in intermediate-risk patients treated with robot-assisted radical prostatectomy (RARP).

Design:

Data from 1143 patients undergoing RARP from January 2013 to October 2020 were collected 901 subjects had available follow-up, of whom 479 were at intermediate risk.

Methods:

PCa progression was defined as biochemical recurrence and/or local recurrence and/or distant metastases. Study endpoints were evaluated by statistical methods including Cox's proportional hazards, Kaplan-Meyer survival curves, and binomial and multinomial logistic regression models.

Results:

After a median (interquartile range) of 35 months (15-57 months), 84 patients (17.5%) had disease progression, which was independently predicted by the percentage of biopsy-positive cores ⩾ 50% and the International Society of Urological Pathology (ISUP) grade group 3 for clinical factors and by ISUP > 2, positive surgical margins and pelvic lymph node invasion for pathological features. Patients were classified into clinical and pathological groups as favorable, unfavorable (one prognostic factor), and adverse (more than one prognostic factor). The risk of PCa progression increased with worsening prognosis through groups. A significant positive association was found between the two groups; consequently, as clinical prognosis worsened, the risk of detecting unfavorable and adverse pathological prognostic clusters increased in both unadjusted and adjusted models.

Conclusion:

The study identified factors predicting disease progression that allowed the computation of highly correlated prognostic groups. As the prognosis worsened, the risk of PCa progression increased. Intermediate-risk PCa needs more prognostic stratification for appropriate management.
A study on 479 patients looked at how prognostic group classification affects progression in patients with intermediate-risk prostate cancer treated with robot-assisted radical prostatectomy Prostate cancer is a serious health concern in men, and those with intermediate-risk prostate cancer may experience disease progression. Urologists use various methods to predict the risk of progression in these patients. However, sometimes the predictions are not accurate. Therefore, researchers conducted a study to identify factors that could help predict disease progression in patients with intermediate-risk prostate cancer who underwent robot-assisted surgery. This study on 479 patients found that a percentage of biopsy-positive cores ⩾ 50% and the International Society of Urological Pathology (ISUP) grade group 3 were predictive factors of disease progression. Additionally, factors like ISUP > 2, positive surgical margins, and pelvic lymph node invasion also predicted disease progression. Patients were classified into three groups based on their clinical and pathological features favorable, unfavorable (one negative prognostic factor), and adverse (more than one negative prognostic factor). The risk of prostate cancer progression increased as the prognosis worsened through these groups. The study concluded that a more accurate stratification of intermediate-risk prostate cancer patients is needed to manage the disease effectively.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Ther Adv Urol Year: 2024 Document type: Article Affiliation country: Italy Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Ther Adv Urol Year: 2024 Document type: Article Affiliation country: Italy Country of publication: United kingdom